Sign in Subscribe
COVID-19

Novavax Secures FDA Approval for COVID-19 Vaccine Amid Controversy

Strategic Insights

— 2 min read

The US FDA has approved Novavax's protein-based COVID-19 vaccine, Nuvaxovid, for adults aged 65 and older, as well as individuals between 12 and 64 with underlying health conditions. The vaccine has been available under emergency use authorization since July 2022. Novavax had initially sought approval for a broader population, but the FDA's decision restricts the vaccine's use. The company remains confident in its shot's ability to play a role in the endemic market, citing market research and CDC statistics indicating that older individuals and those with underlying conditions are most likely to seek vaccination.

Key Takeaways:

  • The FDA has approved Novavax's protein-based COVID-19 vaccine, Nuvaxovid, for adults aged 65 and older, as well as individuals between 12 and 64 with underlying health conditions.
  • The vaccine has been available under emergency use authorization since July 2022.
  • Novavax had initially sought approval for a broader population, but the FDA's decision restricts the vaccine's use.
  • The company remains confident in its shot's ability to play a role in the endemic market, citing market research and CDC statistics indicating that older individuals and those with underlying conditions are most likely to seek vaccination.
  • Novavax must conduct a phase 4, placebo-controlled efficacy and safety study in people between 50 and 64 without high-risk conditions for severe COVID-19, as a post-marketing commitment to the FDA.
  • The company is also required to perform additional trials assessing Nuvaxovid's effect on myocarditis and pericarditis following vaccination.
  • Novavax will receive a $175 million milestone payout from Sanofi, its commercial partner, which will take over marketing duties for the shot later this year.
  • The company expects to be ready to deliver commercial Nuvaxovid doses this fall, coinciding with the upcoming vaccination season.
  • The Nuvaxovid approval may lead to a risk-based approach for COVID vaccine recommendations, rather than universal booster recommendations, as discussed in notes from Leerink Partners and Citi.

Statistics:

  • 175 million: the milestone payout from Sanofi to Novavax upon receiving FDA approval.
  • 500 million: the upfront payment from Sanofi to Novavax under their vaccine platform deal.
  • 65: the minimum age for Nuvaxovid approval.
  • 50-64: the age range for Novavax's phase 4, placebo-controlled efficacy and safety study.
  • $175 million: the milestone payout from Sanofi to Novavax upon receiving FDA approval.
  • May: the month Sanofi made the upfront payment to Novavax.
  • July 2022: the month Nuvaxovid received emergency use authorization.

Sources:

  • FDA approval letter
  • Novavax press release (April 2023)
  • Leerink Partners and Citi notes to clients (April 2023)
  • Sanofi-Novavax vaccine platform deal (May 2022)

Read more